english.prescrire.org > Spotlight > Archives : 2020 > Dupilumab (Dupixent°) and nasal polyps

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

In the November issue of Prescrire International: Dupilumab (Dupixent°) and nasal polyps

FREE DOWNLOAD Dupilumab (Dupixent°) has been authorised in the European Union for adults with very troublesome nasal polyposis. How do Prescrire's editors rate dupilumab in this situation?
Full text available for free download.

Summary

  • Nasal polyposis is a chronic inflammatory condition of the nasal mucosa, with the development of polyps. Patients are troubled, sometimes considerably, by the sensation of having a blocked nose, a partial or complete loss of the sense of smell, taste disturbances and occasionally nasal discharge.
     
  • Dupilumab (Dupixent°) has been authorised in the European Union as an addition to intranasal corticosteroid, for adults with very troublesome nasal polyposis, when an oral corticosteroid is not sufficiently effective or in case of recurrence after surgery.
     
  •  POSSIBLY HELPFUL  For adults with very troublesome nasal polyposis which is not sufficiently relieved by intranasal corticosteroids, oral corticosteroid treatment, given for the shortest possible duration, is one option. Dupilumab appears to be an alternative, because it has a different adverse effect profile. However, it has only been shown to have modest efficacy, which has not been demonstrated in patients whose symptoms are refractory to oral corticosteroids.There are still many unknowns regarding its adverse effect profile, particularly in the long term.

©Prescrire 1 November 2020

Source: "Dupilumab (Dupixent°) and nasal polyps" Prescrire International 2020; 29 (220): 264. Free.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter


Prescrire's rating:

Prescrire's rating
 POSSIBLY HELPFUL 


See also:

"Dupilumab (Dupixent°) in
adults with atopic dermatitis
(May 2019)
Free


Read more:

All the subjects in
Prescrire's Spotlight
Free >